2023-04-30T01:12:17-00:00 2022-12-31 822851604 SECHLER MORGAN CPAS PLLC 2418 W BARROW DRIVE CHANDLER AZ 85224 990EZ 2022-01-01 811809941 CRUSH RETT SYNDROME CRUS 6024211453 602 E RAWHIDE AVE GILBERT AZ 85296 PATRICIA GRAY SECRETARY 6024211453 2023-04-21 true PATRICIA GRAY 999009999 KRISTINA MORGAN CPA P01370742 6022302700 2023-04-21 3 AAL1 IAL1 2022 2023-04-26 12:10:37Z X CrushRett.org X X 77279 X 77279 77279 100000 850 870 101720 -24441 30015 5574 30015 5574 30015 5574 30015 5574 X Raise awareness and support research for Rett Syndrome Crush Rett Syndromes mission is to raise awareness and funding to ultimately find a cure for Rett Syndrome. In 2022, we successfully raised funds through our fundraising events and our social media awareness efforts. 100000 100343 We continued to keep control of our operating expenses by having effective fundraisers that require minimal upfront costs and risks. As a result, we were able to use more funds to support exciting research on ways to cure RS. We granted 100,000 for gene therapy and RNA editing research. Continued on Sch O. . . 100343 Allison Gray President CEO 001.00 0 Patricia Gray Secretary 001.00 0 Katherine Thompson Director 001.00 0 Abbie Moseley Director 001.00 0 false false false false false false false 0 0 0 false false Patricia Gray 602 E Rawhide Ave Gilbert AZ 85296 6024211453 false false false false false false false false false false false NONE NONE true X 93686 100678 153246 130823 77279 555712 93686 100678 153246 130823 77279 555712 28758 526954 555712 0.94830 0.89180 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED Form 990-EZ, Part I, Line 10, Grants Paid Activity Grants to Entities, Grantee Rett Syndrome Research Trust 67 Under Cliff Road Trumbull CT 06611, Cash Grant 100,000, Relationship Form 990-EZ, Part I, Line 16, Other Expenses Administrative Expenses 343 Form 990-EZ, Part I, Line 16, Other Expenses Insurance Expenses 527 Form 990-EZ, Part III, Line 3 We are excited at the news that the first human clinical trial for a potential gene therapy cure has been approved to begin with the first person to receive a dose in the first half of 2023 in Canada. Clinical trials have now also been approved to begin in Europe and USA. Additional research efforts are advancing with alternative approaches for a cure that we are closely watching and supporting. We will continue to be focused on research that will contribute to the development of a cure for Rett Syndrome. Laboratory experiments have provided proof that a cure could reverse the symptoms of Rett Syndrome, even in patients that have lived with these symptoms for many years. The research efforts we are supporting would allow the more than 350,000 people worldwide to live the rest of their lives without being trapped in a body that does not work. It would also allow those yet to be born with Rett Syndrome, one every 90 minutes, to never have to suffer from the horrible symptoms.Crush Rett Syndrome works with other excellent Rett Syndrome organizations to leverage their expertise, medical specialists, and research efforts. This enables us to not use funds duplicating those efforts already being supported by others. Our efforts can be focused on funding research being done throughout the Rett Syndrome community without being confined to just supporting the efforts of one organization. We differentiate ourselves by providing information about Rett syndrome in a way that others can easily understand and share with their network. We continue to grow our Facebook and Instagram followers which helps us to raise awareness and motivate fundraising efforts worldwide. In 2022, the first gene therapy human clinical trial was approved. In 2023, we will see that clinical trial begin with safety results and possibly more data regarding the impact of the gene therapy being reported before the end of the year. Our goal is to raise 25 more in funds and followers than we did in 2023 without decreasing our efficiency.